InMed Pharmaceuticals (IMLFF) Analyzed By Roth Capital; Clearbridge Investments Lowered By $710,600 Its Lam Research (LRCX) Stake

Lam Research Corporation (NASDAQ:LRCX) Logo

Equity research analysts at Roth Capital has begun coverage on shares of InMed Pharmaceuticals Inc (IMLFF) in a research note released on Friday morning, Octafinance.com reports. The broker set “Buy” rating on IMLFF stock.

Clearbridge Investments Llc decreased Lam Research Corp (LRCX) stake by 2.6% reported in 2018Q4 SEC filing. Clearbridge Investments Llc sold 5,225 shares as Lam Research Corp (LRCX)’s stock rose 15.56%. The Clearbridge Investments Llc holds 195,359 shares with $26.60 million value, down from 200,584 last quarter. Lam Research Corp now has $27.83 billion valuation. The stock increased 3.32% or $5.86 during the last trading session, reaching $182.39. About 6.12 million shares traded or 121.57% up from the average. Lam Research Corporation (NASDAQ:LRCX) has declined 6.47% since March 17, 2018 and is downtrending. It has underperformed by 10.84% the S&P500. Some Historical LRCX News: 17/04/2018 – LAM RESEARCH CORP SEES NET INCOME PER DILUTED SHARE $4.77, +/- $0.20 FOR JUNE 2018 QUARTER; 17/04/2018 – Lam Research 3Q EPS $4.33; 14/05/2018 – Iconiq Adds Lam Research, Exits Tempur Sealy: 13F; 17/04/2018 – LAM RESEARCH 3Q ADJ EPS $4.79, EST. $4.39; 27/03/2018 – LAM RESEARCH CORP LRCX.O : MIZUHO STARTS WITH BUY; TARGET PRICE $250; 06/03/2018 – LAM RESEARCH SAYS CY2021 TARGET MODEL FOR ADJ. EPS $23-$25; 06/03/2018 – LAM RESEARCH: ADDED $2B SHARE BUYBACK; 06/03/2018 – Lam Research Corp Announces Cap Return Program; 18/04/2018 – First Lam, Now ASML: People Are Worried About Chip Equipment — Barron’s Blog; 17/04/2018 – Lam Research 3Q Rev $2.89B

InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid therapies. The company has market cap of $73.50 million. The company's lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa. It currently has negative earnings. The firm is also involved in developing INM-085, a cannabinoid topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain.

The stock increased 2.53% or $0.0109 during the last trading session, reaching $0.4419. About 410,786 shares traded. InMed Pharmaceuticals Inc. (IMLFF) has 0.00% since March 17, 2018 and is . It has underperformed by 4.37% the S&P500.

More notable recent InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF) news were published by: Seekingalpha.com which released: “InMed Pharmaceuticals’ Chief Scientific Officer retires – Seeking Alpha” on January 11, 2019, also Seekingalpha.com with their article: “InMed Pharmaceuticals Closer To One-Year Commercialization And Revenues – Seeking Alpha” published on October 16, 2018, Seekingalpha.com published: “InMed Pharmaceuticals announces NSERC grant to the University of British Columbia in support of collaborative R&D work – Seeking Alpha” on September 11, 2018. More interesting news about InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF) were released by: Midasletter.com and their article: “InMed Pharmaceuticals Inc (TSE:IN) Developing Treatment for Epidermolysis Bullosa – Midas Letter” published on January 16, 2019 as well as Midasletter.com‘s news article titled: “InMed Pharmaceuticals (TSE:IN) Commercial-Scale Cannabinoid Manufacturing – Midas Letter” with publication date: November 21, 2018.

More notable recent Lam Research Corporation (NASDAQ:LRCX) news were published by: Nasdaq.com which released: “April 26th Options Now Available For Lam Research (LRCX) – Nasdaq” on March 11, 2019, also Nasdaq.com with their article: “Notable Thursday Option Activity: LRCX, TWTR, CELG – Nasdaq” published on March 14, 2019, Nasdaq.com published: “Nasdaq 100 Movers: TTWO, LRCX – Nasdaq” on March 14, 2019. More interesting news about Lam Research Corporation (NASDAQ:LRCX) were released by: Nasdaq.com and their article: “Lam Research (LRCX) Gains As Market Dips: What You Should Know – Nasdaq” published on March 08, 2019 as well as Seekingalpha.com‘s news article titled: “Semis gain on bottom call, NAND orders – Seeking Alpha” with publication date: March 15, 2019.

Among 9 analysts covering Lam Research (NASDAQ:LRCX), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Lam Research had 12 analyst reports since September 25, 2018 according to SRatingsIntel. Deutsche Bank maintained Lam Research Corporation (NASDAQ:LRCX) rating on Monday, February 25. Deutsche Bank has “Hold” rating and $180 target. The firm earned “Neutral” rating on Tuesday, October 23 by Susquehanna. KeyBanc Capital Markets maintained the shares of LRCX in report on Wednesday, October 17 with “Overweight” rating. The stock has “Hold” rating by Deutsche Bank on Monday, October 1. Citigroup maintained Lam Research Corporation (NASDAQ:LRCX) rating on Friday, March 15. Citigroup has “Buy” rating and $215 target. As per Monday, October 29, the company rating was downgraded by FBR Capital. As per Wednesday, September 26, the company rating was downgraded by UBS. RBC Capital Markets upgraded Lam Research Corporation (NASDAQ:LRCX) rating on Tuesday, January 29. RBC Capital Markets has “Outperform” rating and $190 target. The rating was maintained by Citigroup with “Buy” on Tuesday, September 25. Mizuho downgraded the stock to “Neutral” rating in Monday, October 1 report.

Since February 1, 2019, it had 0 insider purchases, and 2 insider sales for $659,176 activity. Heckart Christine sold $354,616 worth of stock. 1,692 shares were sold by JENNINGS KEVIN, worth $304,560.

Analysts await Lam Research Corporation (NASDAQ:LRCX) to report earnings on April, 16. They expect $3.38 EPS, down 29.44% or $1.41 from last year’s $4.79 per share. LRCX’s profit will be $515.76M for 13.49 P/E if the $3.38 EPS becomes a reality. After $3.87 actual EPS reported by Lam Research Corporation for the previous quarter, Wall Street now forecasts -12.66% negative EPS growth.

Investors sentiment decreased to 0.75 in 2018 Q4. Its down 0.02, from 0.77 in 2018Q3. It dived, as 65 investors sold LRCX shares while 265 reduced holdings. 79 funds opened positions while 169 raised stakes. 146.47 million shares or 9.84% more from 133.35 million shares in 2018Q3 were reported. Wright Invsts Serv accumulated 4,815 shares or 0.28% of the stock. Bp Public Ltd invested in 0.1% or 17,000 shares. Riverhead Cap Management Ltd Liability Company has 4,261 shares for 0.03% of their portfolio. Koshinski Asset Mngmt Inc holds 3,605 shares or 0.12% of its portfolio. 272,124 are owned by Credit Suisse Ag. Kentucky Retirement Ins Fund reported 3,070 shares. Moreover, Stratos Wealth Partners has 0.03% invested in Lam Research Corporation (NASDAQ:LRCX) for 3,966 shares. Pub Employees Retirement Association Of Colorado has invested 0.03% of its portfolio in Lam Research Corporation (NASDAQ:LRCX). Voya Investment Mngmt Limited Co has invested 0.17% in Lam Research Corporation (NASDAQ:LRCX). Kames Capital Public Limited Liability Corp reported 52,808 shares stake. Gam Hldg Ag invested in 0.04% or 6,502 shares. San Francisco Sentry Investment (Ca) invested 0% in Lam Research Corporation (NASDAQ:LRCX). Guinness Atkinson Asset reported 35,800 shares stake. Maryland-based Proshare Advsrs Ltd Company has invested 0.12% in Lam Research Corporation (NASDAQ:LRCX). Platinum Invest Limited reported 0.05% of its portfolio in Lam Research Corporation (NASDAQ:LRCX).

Clearbridge Investments Llc increased Twenty First Centy Fox Inc (NASDAQ:FOX) stake by 55,203 shares to 2.51M valued at $119.88M in 2018Q4. It also upped Yelp Inc (NYSE:YELP) stake by 238,548 shares and now owns 1.16 million shares. Summit Matls Inc was raised too.

Lam Research Corporation (NASDAQ:LRCX) Institutional Positions Chart